Rafferty Asset Management, LLC Igm Biosciences, Inc. Transaction History

Rafferty Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$13.42 - $29.73 $752,284 - $1.67 Million	-56,057 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$27.59 - $66.39 $747,689 - $1.8 Million	27,100 Added 93.59%	56,057 $1.64 Million
Q3 2021 Nov 10, 2021	BUY	$65.76 - $90.65 $214,509 - $295,700	3,262 Added 12.7%	28,957 $1.9 Million
Q2 2021 Aug 10, 2021	SELL	$57.98 - $96.6 $709,791 - $1.18 Million	-12,242 Reduced 32.27%	25,695 $2.14 Million
Q1 2021 May 10, 2021	BUY	$71.56 - $121.23 $2.27 Million - $3.84 Million	31,672 Added 505.54%	37,937 $2.91 Million
Q4 2020 Feb 10, 2021	SELL	$47.41 - $115.03 $103,638 - $251,455	-2,186 Reduced 25.87%	6,265 $553,000
Q3 2020 Nov 13, 2020	BUY	$43.0 - $84.01 $223,514 - $436,683	5,198 Added 159.79%	8,451 $624,000
Q2 2020 Aug 07, 2020	BUY	$51.3 - $75.21 $166,878 - $244,658	3,253 New	3,253 $237,000

21.4M

39.5K

16.5K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $500M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.